{"id":391250,"date":"2015-11-11T00:00:00","date_gmt":"2015-11-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0815-biopharma-ulcerative-colitis-pharmacor-g7-2015\/"},"modified":"2026-04-26T23:43:56","modified_gmt":"2026-04-26T23:43:56","slug":"pcorim0815-biopharma-ulcerative-colitis-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0815-biopharma-ulcerative-colitis-pharmacor-g7-2015\/","title":{"rendered":"Ulcerative Colitis | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 15 September 2015 <\/em><br \/>\nUlcerative colitis (UC) affects approximately 1.25 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however, substantial opportunity exists for new treatment options that can more effectively induce or maintain remission in moderate to severe patients than existing therapies. Vedolizumab (Takeda\u2019s Entyvio) is a recently approved cell adhesion molecule inhibitor that offers a novel mechanism of action. Tofacitinib (Pfizer\u2019s Xeljanz), etrolizumab (Roche\/Genentech), and ozanimod (Receptos) are emerging therapies in late-stage development for moderate to severe UC. This report provides a detailed analysis and an annualized ten-year forecast of the UC market extending into 2024. Detailed epidemiological estimates and in-depth coverage of both current and emerging therapies are also included.<\/p>\n","protected":false},"template":"","class_list":["post-391250","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391250\/revisions"}],"predecessor-version":[{"id":394373,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391250\/revisions\/394373"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}